JUN 11, 2020 7:34 AM PDT

Glowing Chemical Reactions Could Put an End to Bad COVID Tests

WRITTEN BY: Tara Fernandez

Advancements in diagnostic technologies are paving the way for the next generation of ultra-sensitive serological tests — capable of making routine blood tests faster, cheaper, and more accurate than ever before. A collaborative study between researchers at the University of Bologna, together with industry partners Roche and Hitachi, was recently published in Nature Communications, demonstrating the potential of this breakthrough.

Serological diagnostics work by detecting the presence of specific molecules, known as biomarkers, within a patient’s blood sample. Many immunoassays for COVID-19, for instance, indicate that an individual is infected by picking up antibodies against SARS-CoV-2 and, through a series of chemical reactions, create a quantifiable signal. 

One such chemical reaction is a light-emitting mechanism called electrochemiluminescence, or ECL. ECL-based tests are excellent diagnostics as they generally have long shelf lives, can be read in under 20 minutes, and require only tiny volumes of a patient’s blood sample.

Though commonly used, these tests can sometimes fall short in terms of reliability; biomarkers need to reach a certain threshold concentration before they are detectable. The latest developments promise to change that, boosting the sensitivity of ECL-based serological tests by up to 128 percent. This means fewer false negatives and disease being caught at much earlier stages — the weakest link in many currently-available COVID tests.

To achieve this, the team identified a series of novel reactants and imaging techniques to amplify ECL signals and make ECL-based serological tests more efficient. Diagnostic biomarkers would not be limited to measuring levels of antibodies but would also encompass enzymes, proteins, peptides, and hormones, all of which could point to the presence of disease.

Lead researcher at the University of Bologna, Giovanni Valenti commented on the implications of this work, saying, "Our work represents something unprecedented in the field of ECL because it relies on the enhancement of the signal as opposed to the enhancement of the target as it usually happens with enzymatic methods or PCR (Polymerase Chain Reaction)."

"These results pave the way for the development of ultra-sensitive serological tests," Valenti added. 

 

Sources: Technology Networks, Nature Communications


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
DEC 08, 2020
Genetics & Genomics
Advancing Genetic Sequencing with Better Computational Tools
DEC 08, 2020
Advancing Genetic Sequencing with Better Computational Tools
The many advances that have propelled the field of genetics forward have taken a tremendous amount of work in different ...
JAN 06, 2021
Clinical & Molecular DX
COVID Patients Can't Stop and Smell the Roses
JAN 06, 2021
COVID Patients Can't Stop and Smell the Roses
A study of over 2,500 European patients has revealed that 85.9 percent of those with mild COVID-19 symptoms lost their s ...
JAN 27, 2021
Clinical & Molecular DX
No Pain, All the Diagnostic Gain
JAN 27, 2021
No Pain, All the Diagnostic Gain
A recent study published in Nature Biomedical Engineering describes new microneedle patch technology that takes the &ldq ...
FEB 11, 2021
Clinical & Molecular DX
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
FEB 11, 2021
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
Only around half of women diagnosed with breast cancer will benefit from hormonal therapy, a cancer treatment that adds, ...
FEB 25, 2021
Coronavirus
COVID Long-Haulers Get Official Recognition
FEB 25, 2021
COVID Long-Haulers Get Official Recognition
For months, many people that have recovered from cases of COVID-19 have reported experiencing a range of lingering healt ...
MAR 09, 2021
Clinical & Molecular DX
AI Creates Space for Equality in Pain Management
MAR 09, 2021
AI Creates Space for Equality in Pain Management
Pain is experienced more intensely among certain groups of people. Indeed, studies have shown that individuals from mino ...
Loading Comments...